Pfizer Inc. $PFE Shares Acquired by Allen Holding Inc. NY

Allen Holding Inc. NY increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 49.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,519,800 shares of the biopharmaceutical company’s stock after purchasing an additional 500,000 shares during the quarter. Pfizer accounts for 3.7% of Allen Holding Inc. NY’s holdings, making the stock its 4th biggest position. Allen Holding Inc. NY’s holdings in Pfizer were worth $38,725,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter valued at about $29,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer during the second quarter worth about $30,000. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $27.24 on Monday. The firm has a market cap of $154.88 billion, a PE ratio of 20.03 and a beta of 0.47. The stock’s fifty day moving average price is $25.61 and its two-hundred day moving average price is $25.10. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Analyst Ratings Changes

Several equities analysts have recently weighed in on PFE shares. UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. HSBC reissued a “buy” rating and set a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.